Ligand Pharma (LGND) Misses Q1 EPS by 21c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $284.70 --0%
Revenue Growth %: -32.2%
Financial Fact:
Total operating costs and expenses: 16.15M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -32.2%
Financial Fact:
Total operating costs and expenses: 16.15M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $1.63, $0.21 worse than the analyst estimate of $1.84. Revenue for the quarter came in at $51.72 million versus the consensus estimate of $59.07 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Better Home & Finance extends deadline in board removal consent fight
- AIAI Holdings restructures deal to consolidate Messier 42 marketing agreement
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
